11-Mar-2025 6:30 AM CST - Business Wire Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program Agenus Inc. (Agenus or the Company) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipat
25-Feb-2025 7:26 AM CST - Business Wire Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register her
12-Nov-2024 6:00 AM CST - Business Wire Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development Agenus Inc. (Agenus or the Company) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short, said Garo Armen, Ph.D., Chairman and CEO of Agenus. Its potential extends bey
5-Nov-2024 6:30 AM CST - Business Wire Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Co
11-Mar-2025 6:30 AM CST - Business Wire Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program Agenus Inc. (Agenus or the Company) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipat
25-Feb-2025 7:26 AM CST - Business Wire Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register her
12-Nov-2024 6:00 AM CST - Business Wire Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development Agenus Inc. (Agenus or the Company) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short, said Garo Armen, Ph.D., Chairman and CEO of Agenus. Its potential extends bey
5-Nov-2024 6:30 AM CST - Business Wire Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Co
